The table below shows Amylyx Pharmaceuticals, Inc.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
Operating cash flow
-$123.34M
-$167.65M
$11.92M
-$179.87M
-$74.80M
Capital expenditure
$138.00K
$157.00K
$1.24M
$2.53M
$353.00K
Investing cash flow
$14.04M
$75.65M
$92.05M
-$238.99M
-$46.41M
Dividends paid
-
-
-
-
-
Stock buybacks
-
-
-
AMLX operating cash flow (10-K history)
Amylyx Pharmaceuticals, Inc. reported operating cash flow of -$123.34M for fiscal year 2025. That is up 26.4% from -$167.65M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$74.80M (FY 2021) to -$123.34M. Figures come from the company's audited annual reports as filed with the SEC.
